Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 5 - Psychopharmacology of memory

  • from Part I
  • Edited by German E. Berrios, University of Cambridge, John R. Hodges, University of Cambridge
  • Book:
    Memory Disorders in Psychiatric Practice
    Published online:
    06 January 2010
    Print publication:
    16 March 2000, pp 75-98

  • Summary

    The study of the neurochemical modulation of memory has dominated the cognitive psychopharmacological literature, in both humans and animals, in recent years. This chapter concentrates on drug treatments for dementia, since it has been the driving force behind the search for cognitive enhancers. From the results of studies in both animals and humans, the cholinergic system has been the neurotransitter system most traditionally associated with the processes of memory and learning. Evidence of 'subcortical' dementia is noted in patients with Parkinson's disease (PD), where the principal lesion appears to be in the substantia nigra, leading to degeneration of the nigrostriatal dopamine system. The cholinergic hypothesis of Alzheimer's disease (AD) is one of the most enduring and resilient theories of cognitive psychopharmacology. There is accumulating evidence that the serotonergic system is compromised in patients with DAT.